LivaNova (NASDAQ:LIVN) Price Target Raised to $61.00

LivaNova (NASDAQ:LIVN) had its price target raised by Robert W. Baird from $55.00 to $61.00 in a research report sent to investors on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other equities research analysts also recently issued reports about the company. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th. Stifel Nicolaus cut their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Barclays decreased their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Monday, March 17th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.17.

LivaNova Price Performance

Shares of LIVN opened at $44.06 on Thursday. The firm has a market cap of $2.40 billion, a PE ratio of 104.90 and a beta of 0.84. LivaNova has a 1-year low of $32.48 and a 1-year high of $63.57. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $37.89 and a two-hundred day simple moving average of $45.15.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of LIVN. Freestone Grove Partners LP purchased a new stake in shares of LivaNova during the fourth quarter worth about $23,102,000. Artisan Partners Limited Partnership purchased a new stake in LivaNova during the 4th quarter valued at approximately $21,340,000. The Manufacturers Life Insurance Company raised its position in shares of LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock valued at $25,303,000 after buying an additional 339,139 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock worth $34,214,000 after buying an additional 328,313 shares in the last quarter. Finally, LSV Asset Management boosted its position in shares of LivaNova by 278.3% during the first quarter. LSV Asset Management now owns 438,498 shares of the company’s stock worth $17,224,000 after acquiring an additional 322,598 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.